Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
Author:
Affiliation:
1. Optimer Pharmaceuticals, San Diego, CA, USA
Publisher
Microbiology Society
Subject
Microbiology (medical),General Medicine,Microbiology
Reference22 articles.
1. In Vitro Activity of OPT-80 against Clostridium difficile
2. Resistance development, cross-resistance, and synergy studies of OPT-80;Babakhani,2004
3. Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP-1118);Babakhani,2007
4. Activity of OPT-80, a Novel Macrocycle, Compared with Those of Eight Other Agents against Selected Anaerobic Species
Cited by 61 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences;Journal of Antimicrobial Chemotherapy;2024-04-10
2. Semisynthesis of antibiotics;Semisynthesis of Bioactive Compounds and their Biological Activities;2024
3. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models;Clinical Microbiology and Infection;2023-05
4. Make It Less difficile: Understanding Genetic Evolution and Global Spread of Clostridioides difficile;Genes;2022-11-24
5. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?;International Journal of Infectious Diseases;2022-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3